Ajanta Pharma Announces The Launch Of Montelukast Sodium Oral Granules

BRIDGEWATER, N.J., Nov. 16, 2015 /PRNewswire/ -- Ajanta Pharma USA Inc., a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR® Granules, in the US market. Ajanta Pharma offers Montelukast Granules in cartons containing 30 individual sachets.

The approval and launch of the Montelukast Granules is part of an ever-growing portfolio that Ajanta Pharma has developed for the US market. To date, the United States Food & Drug Administration (US FDA) has granted Ajanta Pharma five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the US FDA. 

About Ajanta Pharma
Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished dosages across 35 countries. Its mission is to serve global healthcare needs through empathy, innovation and technology. 

For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.

SINGULAIR® is a registered trademark of Merck & Co., Inc.

Photo - http://photos.prnewswire.com/prnh/20151116/287825

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-montelukast-sodium-oral-granules-300179554.html

SOURCE Ajanta Pharma USA Inc.